Document Classification

Section Type: METHODS

Text: Patients with surgically resected locally advanced (T3-4 or N1-2) or metastatic RCC were randomly assigned to 1 of 4 treatment groups that received different dose levels and schedules of subcutaneous IL-2 as follows : dose level 1, 4 MIU/m2 per day, every other week for 24 weeks (n = 10) ; dose level 2, 8 MIU/m2 per day, every other week for 24 weeks (n = 9) ; dose level 3, 4 MIU/m2 per day, weeks 1-4, 9-12, and 17-20 (n = 11) ; and dose level 4, 8 MIU/m2 per day, weeks 1-4, 9-12, and 17-20 (n = 10).